Altered Expression of Endogenous Soluble Vascular Endothelial Growth Factor Receptor-2 Is Involved in the Progression of Esophageal Squamous Cell Carcinoma

Reduced serum vascular endothelial growth factor receptor-2 (sVEGFR-2) and sVEGFR-1 levels in gastric cancer patients

(2011) Shogo Kikuchi et al.   CANCER SCIENCE

Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors

(2010) Helena Pavlakovic et al.   Annals of the New York Academy of Sciences

The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model

(2010) Masa-Aki Shibata et al.   BMC Medicine

Lymphangiogenesis: Molecular Mechanisms and Future Promise

(2010) Tuomas Tammela et al.   CELL

Neuroblastoma Progression Correlates with Downregulation of the Lymphangiogenesis Inhibitor sVEGFR-2

(2010) J. Becker et al.   CLINICAL CANCER RESEARCH

MicroRNAs and Esophageal Squamous Cell Carcinoma

(2010) Kayoko Matsushima et al.   DIGESTION

The expression of VEGF receptor genes is concurrently influenced by epigenetic gene silencing of the genes and VEGF activation

(2010) Jee Yeon Kim et al.   Epigenetics

Soluble forms of VEGF receptor-1 and -2 promote vascular maturation via mural cell recruitment

(2010) Sophie Lorquet et al.   FASEB JOURNAL

Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth

(2009) Romulo J C Albuquerque et al.   NATURE MEDICINE

NGALR Is Overexpressed and Regulated by Hypomethylation in Esophageal Squamous Cell Carcinoma

(2008) L. Cui et al.   CLINICAL CANCER RESEARCH